DIOVAN HCT Drug Patent Profile

When do Diovan Hct patents expire, and what generic alternatives are available?

Diovan Hct is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in DIOVAN HCT is hydrochlorothiazide; valsartan. There is one drug master file entry for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.

Summary for DIOVAN HCT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	49
Patent Applications:	270
Drug Prices:	Drug price information for DIOVAN HCT
Drug Sales Revenues:	Drug sales revenues for DIOVAN HCT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DIOVAN HCT
What excipients (inactive ingredients) are in DIOVAN HCT?	DIOVAN HCT excipients list
DailyMed Link:	DIOVAN HCT at DailyMed

See drug prices for DIOVAN HCT

See drug sales revenues for DIOVAN HCT

Recent Clinical Trials for DIOVAN HCT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Albany Medical College	Phase 1/Phase 2
ARKAY Therapeutics	Phase 1/Phase 2
LanZhou University	N/A

See all DIOVAN HCT clinical trials

Pharmacology for DIOVAN HCT

Drug Class	Angiotensin 2 Receptor Blocker Thiazide Diuretic
Mechanism of Action	Angiotensin 2 Receptor Antagonists
Physiological Effect	Increased Diuresis

Paragraph IV (Patent) Challenges for DIOVAN HCT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DIOVAN HCT	Tablets	hydrochlorothiazide; valsartan	320 mg/12.5 mg and 320 mg/25 mg	020818	1	2007-02-07
DIOVAN HCT	Tablets	hydrochlorothiazide; valsartan	80 mg/12.5 mg 160 mg/12.5 mg 160 mg/25 mg	020818	1	2005-12-02

US Patents and Regulatory Information for DIOVAN HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-001	Mar 6, 1998	AB	RX	Yes	No
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-003	Jan 17, 2002	AB	RX	Yes	No
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-002	Mar 6, 1998	AB	RX	Yes	No
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-004	Apr 28, 2006	AB	RX	Yes	No
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-005	Apr 28, 2006	AB	RX	Yes	Yes

International Patents for DIOVAN HCT

See the table below for patents covering DIOVAN HCT around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	134624
Australia	644844
Australia	7115191
Canada	2036427	COMPOSES ACYLES (ACYL COMPOUNDS)
Canada	2232775	COMPOSES ACYLES (ACYL COMPOUNDS)
Cyprus	1978	Acyl compounds

Supplementary Protection Certificates for DIOVAN HCT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0443983	91347	Luxembourg		91347, EXPIRES: 20160212
0443983	C00443983/02	Switzerland		PRODUCT NAME: VALSARTAN UND AMLODIPIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57771 22.12.2006
0443983	C300445	Netherlands		PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
0443983	CA 2010 00014	Denmark
0443983	91676	Luxembourg		91676, EXPIRES: 20160212
0443983	C970001	Netherlands		PRODUCT NAME: VALSARTANUM, DESGEWENST IN DE VORM VAN EEN ZOUT OF IN DE VORM V AN EEN ESTER MET EEN HYDROXYVERBINDING MET DE FORMULE R-OH, WAA RIN R EEN LAAGALKYL-, FENYLLAAGALKYL-,LAAGALKENYL-,LAAGALKYNYL- ,LAAGALKOXY-LAAGALKYL-,LAAGALKOXY-LAAGALKENYL-OF LAAGALKOXY-LAA; NAT. REGISTRATION NO/DATE: RVG 20667, RVG 20668 19961104; FIRST REGISTRATION: 36983.00.00, 36983.01.00 19960513

DIOVAN HCT Market Dynamics and Financial Trajectory: Sales Drivers, Competitive Erosion, and Exclusivity/IP Timeline

Last updated: June 26, 2026

Diovan HCT (valsartan/hydrochlorothiazide) is an established US oral combination for hypertension. Financial trajectory is shaped by (1) generic substitution pressure after key patent/exclusivity expirations, (2) prescriber preferences shifting toward other ARB-HCT combinations and higher-uptake combination products, and (3) payer formulary design that rewards lowest net cost and multiple-source availability. The near-term market path in the US is primarily determined by generic launch outcomes for valsartan/HCT and by parallel erosion of branded ARB/HCT share.

What is Diovan HCT (valsartan hydrochlorothiazide) and how does it compete in US hypertension?

Diovan HCT is an angiotensin II receptor blocker (ARB) plus thiazide diuretic fixed-dose combination used in hypertension management. The clinical rationale is additivity: valsartan reduces RAAS-mediated vasoconstriction, and hydrochlorothiazide adds diuretic and antihypertensive effects. This combination sits in a mature category with broad generic supply, making it sensitive to net pricing, rebate structures, and formulary tier placement.

Key US market drivers for ARB-HCT fixed-dose combinations

• Formulary access: Many US plans prefer “step therapy” and tiering to place multi-source ARB-HCT combinations on lower tiers.
• Net price compression: When multiple generic manufacturers launch, branded market share declines first, then net pricing adjusts through rebate renegotiation.
• Therapeutic interchangeability: Patients are often switched within the same dosing equivalence bands because ARB-HCT combinations are therapeutic substitutes.

Competitive set (US)

Diovan HCT faces competition from:

• Other ARB-HCT branded products (where applicable in current formularies)
• Multiple-source generic valsartan/HCT across strengths and manufacturers
• Alternative dual combinations in hypertension (ACEi-HCT, ARB-CCB, ACEi-ARB, etc.), which can displace ARB-HCT when payers optimize for class or individual molecule pricing

When do Diovan HCT patents and exclusivity expire, and when does generic risk peak?

The principal financial inflection is generic entry timing relative to Diovan (valsartan) and HCT combination IP. Generic substitution typically accelerates post-expiration and after any remaining method-of-use, formulation, or combination-specific barriers clear.

US IP and exclusivity structure that drives market share loss

For fixed-dose combinations, generic risk peaks when any remaining:

• Composition-of-matter patents on valsartan or the specific combination are no longer enforceable, and/or
• Regulatory exclusivity (if still relevant to a particular change in labeling) ends, and/or
• Listing-protecting patents in Orange Book are cleared for the specific NDC, dose strength, and dosage form

How exclusivity affects the sales curve

• Pre-expiration: branded sales tend to hold if payer rebates support formulary retention.
• Post-expiration: share loss typically follows a stepped pattern as generic manufacturers ramp volumes and pharmacies fill at lower acquisition costs.
• Post-launch saturation: branded sales stabilize at a low residual level driven by remaining prescriber preference and patient-specific “no substitution” behaviors, often with volume reallocation to lowest-cost generics.

What is the Orange Book status of Diovan HCT and which patents cover what?

Orange Book coverage determines whether ANDA applicants can file with Paragraph IV certifications and what must be “carved out” per listed patent per NDC/strength.

Patent coverage categories that matter commercially

• Composition-of-matter (strongest barrier historically; drives primary generic delay)
• Method-of-use (delays may occur if labels remain covered by active method claims)
• Formulation (can block specific release profiles or excipient approaches)
• Combination-specific claims (fixed-dose combinations can have distinct IP beyond the API patents)

Because the topic is market dynamics and financial trajectory, the commercial key is whether Orange Book listings remain unexpired for the exact dose-strength combinations that drive prescribing and pharmacy substitution.

How does Paragraph IV patent litigation for Diovan HCT affect launch timing and revenues?

Patent litigation can shift generic entry by:

• Stopping or delaying approval/marketing,
• Leading to settlement entry “at risk” dates,
• Or creating a “design-around” that still launches earlier than expected.

Settlement and litigation outcomes that change the revenue curve

Commercial impact is tied to:

• Whether litigation results in a settlement that sets an agreed launch date
• Whether additional patents were asserted and narrowed
• Whether “authorized generics” enter simultaneously or via carve-outs

In hypertension, the timing of first generic launch and subsequent multi-source ramps often matters more than long-tail litigation because payer formularies switch quickly once multiple supply options exist.

What generic entry risks exist for Diovan HCT and how fast does erosion typically occur?

For mature ARB-HCT combinations, the risk is structural: once the key regulatory and IP barriers clear, multiple ANDAs launch, and payers generally accelerate switching. The result is typically:

• Fast first wave: initial generic takes meaningful share.
• Second wave: additional generic entrants increase competition and reinforce payer tier downgrades.
• Residual branded hold: remains for patients who already received branded product or where substitution is constrained.

How does Diovan HCT’s financial trajectory compare with other ARB-HCT combinations?

Category pattern across ARB-HCT

Branded fixed-dose hypertension combinations generally follow a similar financial profile:

1. Branded peak-to-decline as patents approach expiration
2. Stepwise share losses after first generic entry
3. Continued erosion once multi-source supply expands and PBM formulary rules lock in

If a competing product has earlier generic clearances or a more aggressive settlement, it can lead to a faster category reallocation. Conversely, if another product retains stronger Orange Book coverage longer, it can capture residual formulary placements.

What manufacturing and IP barriers can slow generic substitution of valsartan/HCT?

Even when patents expire, entry can be slowed by:

• CMC scale-up and validation for fixed-dose combinations at specific strengths
• Bioequivalence and formulation robustness
• Regulatory or data issues tied to ANDA approvals
• Potential remaining device or process method claims (if any apply to manufacturing processes, though process patents are less common as a primary commercial barrier for oral generics)

For a fixed-dose oral combination, once ANDAs are approved broadly, manufacturing barriers tend to impact the ramp speed rather than stop entry entirely.

How does FDA regulatory status shape Diovan HCT market access and switchability?

Diovan HCT has established use under US marketing authorizations. The commercial lever is not label novelty but regulatory simplicity for generics:

• Once ANDA approvals exist across the strength range, pharmacies can substitute across most common prescriptions.
• If some strengths have later approvals or remaining patent certifications, branded may retain a temporary foothold in those strengths.

For fixed-dose combinations, the strength coverage breadth is a major driver of how quickly prescribers and pharmacists can switch.

Revenue exposure: which dose strengths and NDC coverage drive financial outcomes?

For branded hypertension combos, revenue is concentrated in commonly prescribed strengths. Market share loss depends on:

• Whether generic competition is available across those strengths
• Whether PBMs require substitution at the strength level
• Whether prescribers write for specific strengths that remain temporarily protected or have limited generic supply

Financial trajectory typically tracks the breadth and timing of generic availability across the “core” strength set.

Key market dynamics timeline for Diovan HCT (what to watch as the revenue inflection points)

The following timeline framework captures how branded revenues typically move for an ARB-HCT combination as IP and litigation clear:

Phase 1: Pre-expiration

• Branded maintains formulary position through rebates and contract pricing.
• Generic entry risk rises as ANDA filings and Paragraph IV certifications appear.

Phase 2: First generic marketing

• Revenue decline accelerates as at least one generic is widely stocked.
• PBMs shift to preferred generic tiers once substitution is operational in pharmacy benefit systems.

Phase 3: Multi-source saturation

• Branded share stabilizes at a lower level after multiple generics enter.
• Net price pressure intensifies and branded may face further contract renegotiations.

Phase 4: Residual branded niche

• Remaining branded volume is driven by loyalty, “dispense as written” restrictions, and prescriber habits.
• Market is dominated by lowest-cost generics and supply chain efficiency.

Key Takeaways

• Diovan HCT’s financial trajectory is primarily driven by generic substitution timing for valsartan/HCT and by payer formulary switching mechanics.
• The revenue inflection typically occurs around Orange Book patent clearance and any Paragraph IV litigation settlement dates for the exact NDC strengths that drive routine prescribing.
• Post-first-generic, erosion usually accelerates as multi-source availability expands and PBMs codify lower-tier preferences.
• Manufacturing and regulatory barriers (CMC and bioequivalence per strength) can affect ramp speed but generally do not prevent long-run erosion in mature combination markets.

FAQs

1. How does multi-source generic entry change net pricing for branded ARB-HCT combinations like Diovan HCT?
2. What role do PBM formulary tier changes play in the speed of Diovan HCT sales decline after generic launch?
3. Which Diovan HCT strengths are most sensitive to generic availability gaps during early ANDA entry?
4. How do Paragraph IV settlement terms typically translate into launch calendars for fixed-dose ARB combinations?
5. Can method-of-use or formulation patents delay specific Diovan HCT generic substitutions even after composition patents expire?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
2. FDA Paragraph IV and ANDA regulatory framework materials. US Food and Drug Administration.
3. FDA Drug Approval Reports and labeling history for valsartan/hydrochlorothiazide fixed-dose combinations. US Food and Drug Administration.